RAMM Pharma Corp.
RAMM
CNSX
| 01/31/2025 | 10/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -4.97% | -15.21% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -4.97% | -15.21% | |||
| Cost of Revenue | 51.30% | -14.56% | |||
| Gross Profit | -58.92% | -15.83% | |||
| SG&A Expenses | -72.82% | 212.71% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -94.83% | 1,488.89% | |||
| Total Operating Expenses | -62.28% | 156.27% | |||
| Operating Income | 74.84% | -360.09% | |||
| Income Before Tax | 90.69% | -1,058.04% | |||
| Income Tax Expenses | -1,164.41% | -- | |||
| Earnings from Continuing Operations | 91.44% | -1,058.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 91.44% | -1,058.85% | |||
| EBIT | 74.84% | -360.09% | |||
| EBITDA | 77.61% | -479.13% | |||
| EPS Basic | 91.48% | -1,054.10% | |||
| Normalized Basic EPS | 77.09% | -371.05% | |||
| EPS Diluted | 91.48% | -1,054.10% | |||
| Normalized Diluted EPS | 77.09% | -371.05% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||